Biota Pharmaceuticals Inc news

   Watch this stock
Showing stories 1 - 10 of about 76   

Articles published

BOTA 1.32 -0.05 (-3.65%)
price chart
Biota Pharmaceuticals Incorporated (NASDAQ:BOTA) Shorted Shares Increased 31 ...
Biota Pharmaceuticals Inc. is a biopharmaceutical company. The company has a market cap of $49.20 million. The Firm is focused on the discovery and development of direct-acting antivirals to treat infections.
The Chief Financial Officer of Biota Pharmaceuticals Inc (NASDAQ:BOTA), Mark ...
A few days ago, the Chief Financial Officer of Biota Pharmaceuticals Inc, Mr. Mark Colonnese, acquired a significant amount of company shares - 7,000 , totalling $9,847 USD, calculated based on $1.4 per each share.
Clinical Programs On Track; Biota Reports Q2 Financial Results  Seeking Alpha
Revenue Update on Biota Pharmaceuticals Inc(NASDAQ:BOTA)  Street Edition
Biota Pharmaceuticals Inc (BOTA) Now Covered by Analysts at FBR & Co.
Biota Pharmaceuticals logo Analysts at FBR & Co. began coverage on shares of Biota Pharmaceuticals Inc (NASDAQ:BOTA) in a note issued to investors on Tuesday, Marketbeat reports.
Biota Pharmaceuticals Inc (BOTA) Receives "Outperform" Rating from ...  IRA Market Report
Biota Pharmaceuticals Inc (BOTA) Coverage Initiated at FBR & Co.  Zolmax
Biota Pharmaceuticals Inc (BOTA) Stake Held by Senzar Asset Management, LLC
Biota Pharmaceuticals logo Senzar Asset Management, LLC stated that they own a 5.2% stake in Biota Pharmaceuticals Inc (NASDAQ:BOTA) in a Form 13G disclosure that was filed with the Securities and Exchange Commission (SEC) on Friday, January ...
Biota Pharmaceuticals Inc (BOTA) Stock Rating Reaffirmed by FBR & Co.
Biota Pharmaceuticals logo Biota Pharmaceuticals Inc (NASDAQ:BOTA)'s stock had its “outperform” rating reissued by equities researchers at FBR & Co.
FBR & Co. Begins Coverage on Biota Pharmaceuticals Inc (BOTA)  IRA Market Report
Biota Pharmaceuticals Inc (BOTA) to Post FY2017 Earnings of ($0.49) Per ...  Corvus Business Newswire
Biota Pharmaceuticals Inc Bullish Signal Senzar Asset Management Is In!
Senzar Asset Management has filled a SC 13G form regarding Biota Pharmaceuticals, Inc 1.51 -0.15 -9.04% . Filing Link: 000091957416009407.
Senzar Asset Management, LLC Declares Ownership of Stake in Biota ...  Intercooler Financial
Biota Pharmaceuticals Inc Stock Downgraded (BOTA)
Biota Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery and development of anti-infective products in Australia.
Related articles »  
Biota Pharmaceuticals Inc (BOTA) Earns "Outperform" Rating from FBR & Co.
Biota Pharmaceuticals Inc logo FBR & Co. reaffirmed their outperform rating on shares of Biota Pharmaceuticals Inc (NASDAQ:BOTA) in a research report report published on Monday, AnalystRatings.NET reports. They currently have a $6.00 target price on ...
Biota Pharmaceuticals Incorporated (NASDAQ:BOTA) Sellers Increased By 81.06 ...
Biota Pharmaceuticals Inc. is a biopharmaceutical company. The company has a market cap of $53.07 million. The Firm is focused on the discovery and development of direct-acting antivirals to treat infections.
Biota Pharma (BOTA) Doses First Patient in BTA074 5% Gel Phase 2 as ...  StreetInsider.com
Biota Pharmaceuticals' (BOTA) Outperform Rating Reaffirmed at FBR & Co.  Financial Market News
Biota Pharmaceuticals Inc (BOTA) Earns "Outperform" Rating from Zacks ...
Biota Pharmaceuticals Inc logo Zacks Investment Research reiterated their outperform rating on shares of Biota Pharmaceuticals Inc (NASDAQ:BOTA) in a research note issued to investors on Tuesday morning, MarketBeat.Com reports. Separately, FBR & Co.